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Abstract: Adrenocortical carcinoma (ACC) is a rare cancer with poor prognosis. Mitotane, the
standard treatment for ACC, impairs adrenocortical steroid biosynthesis and cholesterol metabolism.
In the H295R cell line, a standard ACC in vitro model, mitotane was previously reported to enhance
the production of some oxysterols. To verify the possible mechanistic involvement of oxysterols
in the anti-ACC effect of mitotane, a gas chromatography mass spectrometry (GC-MS) profiling of
oxysterols and the main cholesterol precursors was carried out in H295R cells. Among the oxysterols
detected in mitotane-treated cells, 27OHC was markedly produced, as well as lanosterol and
lathosterol cholesterol precursors. In this cell model, mitotane was confirmed to affect mitochondrial
transmembrane potential and induce apoptosis. Such cytotoxic effects were perfectly matched by
H295R cell treatment with a single identical micromolar amount of 27OHC. The mitotane-dependent
strong increase in 27OHC was confirmed in vivo, in the plasma of ACC patients under treatment with
the drug. Moreover, lanosterol, lathosterol, desmosterol and, to a minor extent, 24-hydroxycholesterol
and 25-hydroxycholesterol plasma levels were significantly increased in those patients. The cytotoxic
effect of mitotane on ACC cells may be partly related to the increased intracellular level of 27OHC
induced by the drug itself.
Keywords: mitotane; adrenocortical carcinoma; cholesterol metabolism; 27-hydroxycholesterol;
oxysterols; cytotoxicity; mitochondria; caspase-3; apoptosis
1. Introduction
Adrenocortical carcinoma (ACC) is a rare, aggressive endocrine tumor usually associated with
hypercortisolism and characterized by a poor prognosis [1]. The incidence is about two cases per
million per year, with an overall five-year survival rate ranging between 16% and 47%, which is
mainly influenced by tumor stage [2,3]. The only approved treatment of ACC relies on an old
adrenolytic drug, mitotane, a derivate of the insecticide dichlorodiphenyltrichloroethane (DDT). In
clinical practice, mitotane has shown to be effective both in adjuvant settings and in the treatment
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of advanced/progressive diseases [4,5], but is associated with a number of adverse events, including
hypoadrenalism, hypercholesterolemia, hypertriglyceridemia and central hypothyroidism [6].
Mitotane acts as a steroidogenesis inhibitor inducing mitochondrial functional impairment and
adrenal cortex necrosis, even if the precise mechanism of action is far from being elucidated. Moreover,
it was reported that an increase in mevalonic acid during mitotane administration was associated with
increased cholesterol synthesis [7]. These authors have shown that this effect is due to the known
drug ability to block CYP450-mediated reactions, thus influencing formation of cholesterol oxidized
metabolites responsible for down-regulating hepatic cholesterol synthesis.
Many studies have shown that the mevalonate pathway is up-regulated in several cancers such
as leukemia, lymphoma, multiple myeloma and endocrine tumors [8–10]. Furthermore, cholesterol
depleting agents were used to treat different types of cancers in preclinical models [11,12]. However, the
mechanistic involvement of cholesterol precursors and/or metabolites in ACC progression and in the
therapeutic activity of mitotane are, so far, almost unexplored. Only a single—while seminal—report is
available showing that mitotane is able to induce specific changes in lipid metabolism in ACC cells [13].
In that in vitro study, employing the ACC reference cell line H295, relatively high concentrations of
mitotane were reported to overturn cholesterol synthesis and lead cells to apoptosis, possibly through
the induction of endoplasmic reticulum (ER) stress. Mitotane was demonstrated to markedly increase
the steady-state level of cholesterol precursors lanosterol and lathosterol in H295 ACC cells, but also a
couple of oxysterols of non-enzymatic origin, namely 7-ketocholesterol and 7β-hydroxycholesterol [13],
the latter two compounds being well known as potentially toxic lipid oxidation products [14,15].
Based on those findings, the main aim of this study was to provide additional mechanistic hints on
both the beneficial and adverse effects of mitotane, by focusing on the oxysterol profile induced by this
drug in the H295 cell line and also directly in ACC patients. Specific oxysterols might be relevant for
the action of mitotane at the cellular level and could represent useful response markers to be exploited
in clinical practice.
Here, we report on: (1) the specific increase of 27OHC, the major oxysterol of pathophysiological
relevance, in H295R cells challenged with a mitotane concentration confirmed to exert toxic and
proapoptotic effects; (2) the reproduction of such observed mitotane toxicity in vitro by adding an
identical micromolar amount of 27OHC instead of the drug to the incubation medium of H295R
cells; (3) the marked increase of 27OHC in the peripheral blood of ACC patients, under therapy
with mitotane.
2. Materials and Methods
2.1. Cell Culture and Chemical Reagents
The H295R cell line, the adherent variant of H295 cell line, was supplied from the American
Type Culture Collection (ATCC, Rockville, MD, USA). The H295R cells were cultured in a 1:1 mixture
of Dulbecco’s Modified Eagle’s Medium (DMEM) (Corning, New York, NY, USA) and Ham’s F-12
Nutrient mixture (F12) (Corning, New York, NY, USA) supplemented with 2 mmol/L L-glutamine,
penicillin (25 units/mL), and streptomycin (25 mg/mL, all from Sigma-Aldrich, Saint Louis, MO,
USA) and 2.5% of Nu-Serum (Corning, New York, NY, USA) and enriched with 1% di ITS + Premix
(Corning). Cells were incubated with mitotane (Supelco, Bellefonte, USA) dissolved in 100% methanol
(Sigma-Aldrich, Saint Louis, MO, USA) or 27OHC (Avanti Polar Lipids, Alabaster, AL, USA). dissolved
in 100% ethanol.
All oxysterols of enzymatic origin detectable in human plasma [16] were considered, namely
24-hydroxycholesterol, 25-hydroxycholesterol, 27-hydroxycholesterol, 7-α-hydroxycholesterol, plus
the two oxysterols of non-enzymatic origin, namely 7-ketocholesterol and 7-β-hydroxycholesterol,
already detected in the mitotane-treated H295 cell line [13]. Their deuterated forms used as internal
standards for gas chromatography mass spectrometry analyses were obtained from Avanti Polar Lipids
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(Alabaster, AL, USA). All other not specified reagents and chemicals were obtained from Sigma Aldrich
(Saint Louis, MO, USA).
2.2. Recruited Individuals and Patients
For the reported study, we selected 14 ACC patients and 5 healthy individuals. Their plasma
samples were part of a large biorepository of biological samples available at the University of Torino,
Internal Medicine-San Luigi Hospital (Orbassano, Turin, Italy). The study protocol includes storage
of biomaterials of ACC patients with the aim to search for predictors of response to treatment and
prognostic markers. In agreement with the ethical guidelines of the 1975 Declaration of Helsinki, it
was approved by the local Ethical Committee (San Luigi Hospital, Orbassano, Italy, n. 36/2012). All
the selected plasma samples were anonymized by an Internal Medicine staff member not involved in
the study. Inclusion criteria for ACC patients were as follows: pathologically confirmed diagnosis of
ACC, mitotane therapy for at least 12 months, regular determination of plasma mitotane concentration,
mitotane plasma concentration in therapeutic range (14–20 mg/L), total cholesterol levels >190 mg/dL
after mitotane treatment (Table 1). Tumor stage was established according to the ENSAT classification:
stage I, confined tumor, ≤5 cm; stage II, confined tumor, >5 cm [3]. Clinical data were available for all
patients. A written informed consent for the analysis of plasma oxysterols and related intermediate
products of cholesterol was obtained from each person recruited in the study (Table 1).
Table 1. Clinical features of adrenocortical carcinoma (ACC) patients.
Subjects Gender ACCStage
Disease
Status Mitotane
Mitotane
Levels (µg/mL)
Total Chol.
Levels (mg/dL)
Cortisol Levels
(µg/dL)
1 M II NED yes 7.47 218 2.20
2 F I NED yes 9.55 251 1.50
3 M II AWD-DOD yes 9.97 197 22.30
4 F II AWD-DOD yes 7.04 334 1.83
5 F I NED yes 10.85 259 1.86
6 F II NED yes 8.15 216 <1
7 F I NED yes 4.12 261 12.80
8 F II NED yes 13.29 251 6.75
9 F II NED yes 19.36 225 2.37
10 F II NED yes 14.19 246 1.20
11 F II NED yes 15.94 204 2.35
12 M II NED yes 14.43 202 2.56
13 F II AWD yes 14.59 259 2.11
14 F II NED yes 17.89 464 <1
M: male; F: female; I, II stages: see Methods 2.2; NED: No Evidence of Disease; AWD: Alive With Disease; DOD:
Dead Of Disease.
2.3. Cholesterol Precursors and Oxysterols Quantification
For in vitro quantification, H295R cells were seeded into 6-well plates and treated with mitotane
(5 or 10 µM) for 24, 48 or 72 h, as described in the result section. After the incubation times, ACC
cell pellets were collected then added to a screw-capped vial sealed with a Teflon septum together
with 1000 ng of D7-lathosterol, 50 ng of D6-lanosterol, 50 ng of D7-7α-hydroxycholesterol, 50 ng of
D7-7β-hydroxycholesterol, 50 ng of D7-7-oxo-cholesterol, 50 ng of D6-24-hydroxycholesterol, 50 ng
of D6-25-hydroxycholesterol, 50 ng of D6-27-hydroxycholesterol as internal standards, plus 50 µL of
butylated hydroxytoluene (5 g/L) and 50 µL of K3- ethylenediaminetetraacetic acid (EDTA) (10 g/L) to
prevent auto-oxidation. Each vial was flushed with argon for 10 min to remove air. Alkaline hydrolysis
was allowed to proceed at room temperature (22 ◦C) with magnetic stirring for 60 min in the presence of
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ethanolic 1 M potassium hydroxide solution. After hydrolysis, the sterols were extracted twice with 5 mL
cyclohexane. Oxysterols were eluted on solid phase extraction (SPE) cartridge (Waters, Milford, MA,
USA) by isopropanol:hexane 30:70 v/v. The organic solvents were evaporated under a gentle stream of
argon and converted into trimethylsilyl ethers with N,O-Bis(trimethylsilyl)trifluoroacetamide (BSTFA).
For in vivo quantification, 0.25 mL of plasma of ACC patients and control were added to a
screw-capped vial sealed with a Teflon septum, together with deuterium labelled or structural
homologous internal standards, butylated hydroxytoluene (BHT) and EDTA and processed as
described above.
Gas chromatography mass spectrometry (GC-MS) analysis was performed on a GC equipped with
an Elite column (30 m × 0.32 mmid × 0.25 mm film; Perkin Elmer, Waltham, MA, USA) and injection
was performed in splitless mode and using helium (1 mL/min) as a carrier gas. The temperature
program was as follows: initial temperature of 180 ◦C was held for 1 min, followed by a linear ramp of
20 ◦C/min to 270 ◦C, and then a linear ramp of 5 ◦C/min to 290 ◦C, which was held for 10 min. The
mass spectrometer operates in the selected ion-monitoring mode. Peak integration was performed
manually, and sterols were quantified from selected-ion monitoring analysis against internal standards
using standard curves for the listed sterols. Additional qualifier (characteristic fragment ions) ions
were used for structural identification [17–19].
2.4. Oxysterol Challenge and Cytotoxicity Assay
H295R cells were seeded into 96-well plates in triplicates and incubated for 48 h in the absence or
in the presence of increasing concentrations of 27-hydroxycholesterol or mitotane (2.5, 5, 7.5, 10 µM)
for 48 h. Concentrations of 27OHC are in a range comparable with the oxysterol’s levels quantified
in ACC cell supernatants by GC-MS analysis. The cell proliferation reagent WST-1 (Roche Applied
Science, Penzberg, Germany), based on recording formazan dye production by metabolically intact
cells, was used to measure the potential toxic effect of different concentrations of 27OHC and mitotane
on H295R cells. The tetrazolium salt WST-1 was added to each well at the end of cell treatments with
mitotane or 27OHC: the produced water-soluble formazan was measured after 30 min by using a
microplate reader (iMARK microplate reader, Biorad Life Science Group, Hercules, CA USA) at 450 nm
wavelength (630 nm was considered as reference wavelength).
2.5. JC-1 Labelling
H295R cells were incubated with 5, 10 µM mitotane or 5, 10 µM 27-hydroxycholesterol at 37 ◦C for
48 h. Cells were pre-incubated with 10 µg/mL JC-1 dissolved in DMEM/F12 at 37 ◦C for 10 min. The
cationic dye 5,5′,6,6′-Tetrachloro1,1′,3,3′-tetraethyl benzimidazolylcarbocyanine iodide (JC-1) (Life
Technologies, Monza, Italy) exhibits membrane-potential-dependent accumulation in mitochondria as
J-aggregates that can be detected by red fluorescence. When mitochondria are depolarized, JC-1 is
converted into a monomer displaying green fluorescence, which is considered as an index of apoptosis;
the red fluorescence (590 nm) and green fluorescence (530 nm) were detected by using a 96-well plate
Luminometer (GloMax, Promega, Milan, Italy). Mitochondrial polarization state was evaluated as the
ratio between red and green fluorescence.
2.6. Evaluation of Caspase-3 Activity
After 48 h treatment with mitotane, H295R cells were collected by centrifugation, washed
with cold 0.1 M phosphate buffered saline (PBS), and suspended in 600 µL ice-cold lysis buffer
[25 mM 4-2-hydroxyethyl-1-piperazineethansulphonic acid (HEPES), 5 mM MgCl2, 5 mM EDTA,
5 mM dithiothreitol, 2 mM phenylmethylsulphonyl fluoride] for 15 min; the suspension was
frozen/thawed 10 times (liquid nitrogen/37 ◦C) and centrifuged at high speed for 30 min at 4 ◦C
and the supernatant was collected. The samples were diluted to achieve a protein concentration of
0.5 mg/mL and incubated for 45 min at 37 ◦C with 65 µM (final concentration) fluorogenic substrate
N-Acetyl-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin (Ac-DEVD-AMC). Caspase-3 activity was
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evaluated as the release of fluorescent 7-amino-4-methylcoumarin (AMC), using a 96 Microplate
Luminometer (GloMax, Promega, Milan, Italy) and recording ∆ min fluorescence at 380 nm excitation
and 510 nm emission. Fluorescence was referred to AMC standard curve (ranging from 10 nM to
10 µM). Proteins were evaluated with the Bio-Rad protein assay dye reagent (Bio-Rad, Milano, Italy).
2.7. Statistical Analysis
Statistical differences between mitotane treated and untreated cells and between ACC patients
and controls were evaluated using Student’s t-test and a one-way Analysis of Variance (ANOVA) test
associated with the Bonferroni’s multiple comparison post-test. Data were analyzed with GraphPad
Prism 6 software (San Diego, CA, USA) and results were expressed as mean ± Standard Deviation (SD).
3. Results
3.1. Effect of Mitotane on Cholesterol Precursors and Oxysterols Profile in the Standard Human Adrenal Cancer
Cell Line
A net modification in the pattern of cholesterol precursors and oxysterols was observed in H295R
cells after a 48 h exposure to 10 µM mitotane. As reported in Table 2, total cholesterol recovered
by GC-MS in mitotane treated H295R cells showed a 1.5-times increase as compared to untreated
cells. In addition, lanosterol and lathosterol resulted significantly higher in the mitotane-treated cell
pellets than in untreated cell pellets, showing a 1.7- and 1.6-times increase respectively; conversely,
desmosterol markedly dropped in mitotane treated H295R cells, being five times lower than in control
cells. Again, in Table 2, the content of 7KC and 7βOHC did not show any significant difference
between treated and untreated cells. Moreover, a slight significant decrease was observed for 7αOHC,
the only B ring enzymatic oxysterol of pathophysiological relevance [14,15]. With regard to the side
chain oxysterol of major relevance detectable in human peripheral blood, 24OHC and 25OHC were
practically undetectable in H295R cells both mitotane-treated or not. Interestingly, only 27OHC was
detectable in this cell line, and the adopted 10 µM mitotane treatment stimulated its cellular content up
to 4.6 times as to the constitutive level (Table 2).
Table 2. Cholesterol, cholesterol precursors and oxysterols in H295R cells.
Sterols Untreated H295R Cells Mitotane Treated H295R Cells
µg/108 cells µg/108 cells
Cholesterol 106 ± 30 157 ± 56 ***
ng/108 cells ng/108 cells
Lanosterol 1092 ± 44 1897 ± 176 ***
Desmosterol 4290 ± 244 865 ± 43 ***
Lathosterol 1040 ± 69 1631 ± 147 ***
7-Ketocholesterol 55 ± 1 50 ± 3
7α-hydroxycholesterol 34 ± 2 21 ± 8 *
7β-hydroxycholesterol 34 ± 1 25 ± 4
24-hydroxycholesterol n.d. n.d.
25-hydroxycholesterol n.d. n.d.
27-hydroxycholesterol 28 ± 5 130 ± 5 ***
H295R cells were treated with 10 µM mitotane for 48 h and GC-MS analyses were evaluated on collected cell pellets.
Data are referred as means ± SD of three independent experiments; n.d.: not detectable. Significantly different
versus untreated cells: * p < 0.05, *** p < 0.001.
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Further assessment of 27OHC intracellular level against time was performed, also including a
5-µM mitotane treatment. As reported in Figure 1, in the presence of either 5- or 10-µM mitotane a
net increase of the H295R oxysterol content was observed already after 24 h incubation. While the
27OHC content remained stable within 5-µM mitotane-treated cells, it kept increasing with time in
10-µM mitotane-treated cells.
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Figure 1. Production of 27-Hydroxycholesterol by H295R cell treatment with mitotane. H295R cells
were incubated at 37 ◦C up to 72 h, in the absence or in the presence of two different concentrations of
mitotane, namely 5 and 10 µM. Data are reported as means ± SD from three independent experiments,
after normalization for the cell number, and are expressed in ng/108 cells. Significantly different versus
untreated cells: ** p< 0.01; *** p < 0.001.
3.2. Effect of Mitotane and 27OHC on Viability of H295R Human Adrenal Cancer Cells
Here, preliminary unreported analyses showed that the 48-h challenge with 27OHC actually
affected H295R cell viability exhibiting an IC50 of 28.72µM± 1.87. On this basis, all further experimental
observations were carried out at 48 h of incubation time, using 10 µM as maximal oxysterol final
concentration in the cell incubation medium. In the latter amount, 27OHC caused about a 20% fall in
cell viability, after 48 h of treatment, while 5-µM 27OHC only slightly affected this parameter (Figure 2,
Panel A). With regard to mitotane, after the 48-h cell challenge, a 5 µM final concentration reduced of
about 10% cell viability as for 5-µM 27OHC, while a 10 µM concentration affected cell viability slightly
more than 10-µM 27OHC (Figure 2, panel A).
3.3. Impairment of Mitochondrial Transmembrane Potential by Mitotane and 27OHC
Since mitotane was already known to impair mitochondrial function [7], the possible effect on
mitochondrial transmembrane potential by the employed dose of this drug was then assessed. Indeed, a
fairly moderate decrease in the aggregate fluorescent count, showing a depolarization in mitochondrial
membrane, was observed after both 5- and 10-µM mitotane treatments, being statistically significant
at the higher drug’s dosing (Figure 2, Panel B). An almost identical impairment of mitochondrial
transmembrane potential was detectable when H295R cells were incubated for 48 h at 37 ◦C in the
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presence of either 5 µM and 10 µM 27OHC. In this case also, a statistical significance was achieved at
the oxysterol’s higher concentration (Figure 2, panel B).
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Figure 2. Effect of 27-hydroxycholesterol and mitotane on H295R cell viability and apoptosis. (A) Cells
were treated for 48 h with increasing concentrations of 27OHC or mitotane (0–10 µM). For the WST-1
test see Methods 2.4. Data are reported as means ± SD from three independent experiments and
expressed as % of viable cells compared to control (untreated cells): § p < 0.05, §§ p < 0.01, *** p < 0.001.
(B) Mitochondrial polarization state in H295R cells treated with 5 or 10 µM 27OHC or with 5 or
10 µM mitotane for 48h. For the JC-1 assay see Methods 2.5. Data are means ± S.D. of three different
experiments. Significantly different vers s tr t c lls: * p < .05. (C) Caspase-3 specific activity in
H295R cells treated with 5 or 10 µ 2 t tane for 48h. AMC: 7-amino 4-methylcoumarin
(see Methods 2.6.) Data are S. . of thr e different experiments. Significantly different versus
untreated cells: * . , *** p < .001.
3.4. Apoptotic Effect of Mitotane and 27OHC on H295R Cells
The mitotane treatment carried out on the employed cancer cell line showed to be markedly
effective in activati g caspase-3 after 48 h, moderately increasing in 10-µM-treated cells in comparison
to 5-µM-treated ones (Figure 2, Pa el C). Not bly, iden ical micromolar concentrations of 27OHC
perfectly match d the mitotane induced caspas -3 activ ti n, with o apparent difference in efficacy
between the two concentrations used (Figure 2, Panel C).
3.5. Changes in Cholesterol Synthetic and Oxidative Pathways in ACC Patients
A number of relevant metabolic alterations were observed in the recruited patients undergoing
mitotane treatment as compared to the disease-free individuals.
Despite no correlation between mitotane and cholesterol blood levels being observed in ACC
patients (Table 1), the upstream cholesterol precursor lanosterol and the downstream cholesterol
precursor desmosterol showed 2.8- and 2.6-fold significant increases in the plasma from mitotane-treated
ACC patients compared to controls, respectively (Table 3). A much higher value was observed for
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lathosterol, the other key downstream cholesterol precursor, which resulted in four-fold increase
compared with controls.
Table 3. Profiling of key cholesterol precursors and of enzymatic oxysterols in plasma of controls and
ACC patients.
Subjects Lanosterol(ug/L)
Desmosterol
(ug/L)
Lathosterol
(ug/L)
24OHC
(ug/L)
25OHC
(ug/L)
27OHC
(ug/L)
Controls (n = 5) 65 ± 7 522 ± 59 764 ± 40 22 ± 6 11 ± 5 39 ± 3
ACC
post-mitotane (n = 14) 186 ± 83 ** 1339 ± 539 3054 ± 872 *** 48 ± 13 *** 18 ± 5 * 142 ± 34 ***
Number of subjects are reported in parentheses (n). Plasma transfusion bags were used for control analyses. Values
are means ± SD. Significantly different versus controls: * p < 0.05, ** p < 0.01, *** p < 0.001.
Moreover, plasma levels of the three oxysterols of enzymatic origin and of major pathophysiological
interest exhibited quite a different behavior in mitotane treated neoplastic patients in comparison to
control (Table 3). A modest increment, just statistically significant as compared to the control, was
observed in neoplastic patients with regard to plasma 25OHC level. On the contrary, a much higher
and more statistically meaningful increase in ACC group was shown by plasma 24OHC and by 27OHC.
Notably, even though no correlation between 27OHC and cholesterol plasma levels was found in the
single ACC patient, 24OHC doubled the control mean value, while the 27OHC plasma level reached
an increase of 3.6 times.
4. Discussion
A detailed investigation of the molecular mechanisms that underlie the therapeutic effect
of mitotane on ACC is necessary to improve the clinical handling of the drug. Along this line,
the elucidation of mitotane modulation of cholesterol oxidation pathway appears useful. In a
comprehensive in vitro study of the specific lipid changes provoked by mitotane, Sbiera and colleagues
recently showed, for the first time, that this drug is able to perturbate the cholesterol oxidation
pathway [13]. Namely, they reported that the challenge of H295 cells with a single dose of 50 or 100 µM
mitotane significantly increased the intracellular steady-state level of 7KC and 7βOHC as to mitotane
untreated cells [13]. Only these two oxysterols of non-enzymatic origin were measured, as the study
was not focused on oxidative cholesterol metabolism.
This observation prompted us to investigate mitotane effect on the main oxysterols of recognized
pathophysiological meaning, not only in vitro but also in vivo. The most meaningful finding both
in in vitro (Table 2 and Figure 1) and in vivo (Table 3) was the fact that the treatment with mitotane
led to a marked increase of 27-hydroxycholesterol, as measured by GC-MS standard methodology.
The oxysterol 27OHC is the product of cholesterol oxidation by the ubiquitous and constitutive
mitochondrial hydroxylase CYP27A1 [20] and represents the most abundant oxysterol in human
plasma [21]. The role of this oxysterol in cancer is highly debated and related literature is quite
controversial, given that different experimental approaches and conditions were employed, a wide
variety of cancer types was assessed [22], and the oxysterol content varied significantly in the single
tumors [23]. As far as human adrenal cancer cells are concerned, this paper provides solid evidence of
specific cytotoxic and pro-apoptotic actions of 27OHC, which matches the in vitro effect exerted by an
identical micromolar amount of mitotane (Figure 2). Indeed, a significant contribution of 27OHC to
the anti-ACC action of mitotane could be viewed as very likely. The higher cytotoxicity of mitotane as
to 27OHC observed in H295 cells treated with 10 µM concentration (Figure 2, Panel A), could be due
to a derangement of plasma membrane ion channels, similar to that exerted by DDT, the mitotane
parental compound. This hypothesis will be certainly checked in future studies.
The content of two other side-chain oxysterols—24OHC and 25OHC—increased, even if it was
to a lesser extent, in ACC patients (Table 3). Their possible involvement in the therapeutic effect of
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mitotane cannot be excluded, even though in the standard in vitro ACC model, i.e., the H295R cell line,
they were not detectable (Table 2).
Of note, as shown in Table 2, no significant increase of 7KC and 7βOHC in mitotane-treated
as to untreated H295R cells was detected. Such a diverging finding from that reported by Sbiera
and colleagues using the same cell line [13] could be, at least in part, due to the markedly different
concentration range of mitotane adopted and its related cytotoxicity.
In the present paper, the cell treatment consisted of 5 or 10 µM mitotane, the latter affecting
cell viability by 30% at 48 h incubation (Figure 2, Panel A), while in the quoted report mitotane
concentrations ranged between 50 and 100 µM [13], i.e., one order of magnitude higher compared
to those employed in the present experiments. At such relatively high drug concentrations, cell
viability was reduced by 80% after 24 h incubation [13]. This cell condition could have favored
the non-enzymatic oxidation of cholesterol with a consequent rise of 7KC and 7βOHC. Side chain
oxysterols were not considered in that study.
With regard to the cholesterol synthesis pathway, a 48 h challenge of H295R cells with 10 µM
mitotane induced a 1.5 times higher amount of cholesterol in comparison to untreated cells (see Results,
Sub-Chapter 3.2), with a net increase in lanosterol, upstream cholesterol precursor, and in lathosterol
(Table 2), the intermediate metabolite of the Kandutsch–Russell pathway of cholesterol synthesis. The
parallel drop of desmosterol, the final intermediate of the Bloch pathway of cholesterol synthesis,
confirmed that in the H295 cell line the first of the two pathways was, by far, prevalent. These in vitro
findings, in this case, corresponded to those obtained by Sbiera and colleagues [13]. It is of interest
that the quantification of cholesterol precursors in the plasma of our ACC patients demonstrated
an increased activation of both cholesterol synthetic pathways during the treatment with mitotane
(Table 3), while total cholesterol levels showed a wide variability in the different patients (Table 1).
Moreover, no correlation was found in the individual patients between mitotane and cholesterol or
27OHC at least at the single time point considered in this study. Future studies will imply a larger
number of patients and prospective follow-up evaluations.
Our samples included only patients with Stage I or II ACC, and this is explained by three reasons:
(i) our institution is a referral center in Italy for ACC treatment with specific expertise in adjuvant
mitotane therapy; therefore, our recruitment pattern consists of early stage ACC patients in more
than half of the cases [24]; (ii) patients with advanced disease are often treated with the association of
mitotane and chemotherapy [25], which could have interfered with our analysis; (iii) patients with
Stage I and II have higher chances of survival [3], allowing a better appraisal of mitotane effect. It is
known that administration of mitotane is aimed to target plasma mitotane concentrations between 14
and 20 mg/L, which have been associated with the drug efficacy (“therapeutic window”) [24–27], but
during follow-up there are fluctuations of plasma mitotane levels. A prospective study is necessary to
evaluate changes of the 27OHC plasma concentrations in relation to variations of plasma mitotane
values, which could potentially pave the way to the use of 27OHC levels to monitor the mitotane
therapeutic response. Therefore, regarding the in vivo analyses, limitations refer to the limited number
of ACC patients available for the study.
Moreover, it may be of interest to evaluate the changes of 27OHC levels after mitotane exposition
in other cell lines also, focusing on the endocrine glands other than adrenals (i.e., pituitary) that are
affected by mitotane both in vitro [28,29] and in vivo [30,31].
To summarize, the main findings of this study are: (1) mitotane treatment induces a net increase
in 27OHC in ACC cells and in ACC patients; (2) 27OHC is responsible for at least part of the cytotoxic
and pro-apoptotic effects exerted by mitotane on ACC cells.
5. Conclusions
GC-MS quantification of the main cholesterol precursors and oxysterols in the standard ACC
cell line as well as in the plasma of ACC patients undergoing mitotane treatment confirms a marked
modulation of steroidogenesis, and identifies a remarkable feature of mitotane action in the rise of
Cells 2020, 9, 885 10 of 12
27-hydroxycholesterol. Only a prospective study will permit the evaluation of a possible correlation
between the increase in 27OHC and the therapeutic efficacy of mitotane. Nevertheless, 27OHC appears
to be a promising candidate marker of mitotane action.
Moreover, the novel findings provided here could shed further light on the mitotane mechanism
of action. Part of the specific cytotoxic effect of mitotane on ACC cells seems related to the increased
intracellular amount of 27OHC induced by the drug. Pertinently, this oxysterol was demonstrated to
impair mitochondrial function and induce apoptosis in ACC cells to a similar extent as mitotane.
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